Amphastar Pharmaceuticals Bundle
Who Really Owns Amphastar Pharmaceuticals?
Understanding the ownership structure of a company is crucial for investors and stakeholders alike. The journey of Amphastar Pharmaceuticals SWOT Analysis, a key player in the pharmaceutical company landscape, from a private entity to a publicly traded one, offers a fascinating case study in corporate governance. This exploration dives into the evolution of Amphastar ownership, revealing the key players shaping its destiny.
From its IPO in 2014, Amphastar Pharmaceuticals' ownership has evolved, impacting its strategic direction and market performance. This analysis will uncover the significant shifts in Amphastar ownership, including the influence of major shareholders and the impact on the company's financial success, including its impressive 2024 financial results. Discovering the answers to "Who owns Amphastar" and understanding the company information is essential for anyone looking to invest or understand the pharmaceutical industry. This deep dive into Amphastar's investor relations provides valuable insights.
Who Founded Amphastar Pharmaceuticals?
The inception of Amphastar Pharmaceuticals, Inc. in 1996 marked the beginning of a journey led by its co-founders, Dr. Jack Yongfeng Zhang and Dr. Mary Ziping Luo. Their combined expertise and initial investments were crucial in establishing the company's early focus on complex pharmaceutical products. This foundational ownership structure set the stage for Amphastar's development within the competitive pharmaceutical industry.
Dr. Zhang and Dr. Luo, with their extensive backgrounds, spearheaded the company's strategic direction. Dr. Zhang, as CEO, President, and Chief Scientific Officer, and Dr. Luo, as Chief Operating Officer, Chief Scientist, and Chairwoman, have played pivotal roles in shaping Amphastar's operational and scientific strategies. The early ownership structure, though not publicly detailed in terms of specific equity splits, was built on private funding and the founders' contributions, typical of early-stage biopharmaceutical companies.
The founders' deep understanding of the pharmaceutical sector, combined with their initial investments, provided the necessary resources for Amphastar's early development and strategic focus. This early phase was characterized by a commitment to technically challenging products, setting the stage for Amphastar's future growth and market position.
Dr. Jack Yongfeng Zhang
Dr. Zhang has been the CEO and a board member since the company's founding. He also holds the positions of President and Chief Scientific Officer.
Dr. Mary Ziping Luo
Dr. Luo co-founded the company and currently serves as the Chief Operating Officer, Chief Scientist, and Chairwoman of the Board of Directors.
Early Funding
Operations began with private funding and contributions from the founders, typical of early-stage biopharmaceutical ventures.
Dr. Zhang's Background
He co-founded Applied Physics and Chemistry Laboratories, Inc. (APCL) in May 1989 and holds a Ph.D. in chemistry from the State University of New York at Stony Brook.
Dr. Luo's Experience
Dr. Luo brings over 30 years of experience, primarily focusing on intellectual property development and managing training programs.
Strategic Focus
The company's early focus was on technically challenging products, leveraging the founders' expertise.
Key Takeaways on Amphastar Ownership
Understanding the initial ownership structure of a pharmaceutical company like Amphastar Pharmaceuticals is crucial for investors. The founders' roles and backgrounds highlight the importance of scientific expertise and strategic leadership in the biopharmaceutical sector. For those interested in Amphastar ownership and its financial performance, further details can be found in the company's investor relations materials, including its annual reports and SEC filings. For more insights, consider reading this article about Amphastar Pharmaceuticals.
- Dr. Zhang and Dr. Luo co-founded the company.
- Early operations were funded privately.
- The founders' expertise shaped the company's strategic focus.
- The leadership team has remained consistent over time.
Amphastar Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Amphastar Pharmaceuticals’s Ownership Changed Over Time?
The journey of Amphastar Pharmaceuticals into the public domain began on June 25, 2014. The company initiated its Initial Public Offering (IPO) on the NASDAQ Global Select Market, trading under the symbol 'AMPH'. The IPO saw the offering of 8,000,000 shares, priced at $7.00 each. This raised a total of $56,000,000, which was instrumental in fueling expansion, research and development, and debt management for the Pharmaceutical company.
The shift to being publicly traded marked a significant change in the Amphastar ownership structure. This transition allowed for a broader investor base and provided the company with access to capital markets. This move was a strategic step that set the stage for future growth and development within the pharmaceutical industry. For more insights, you can explore the Competitors Landscape of Amphastar Pharmaceuticals.
| Key Dates | Event | Impact on Ownership |
|---|---|---|
| June 25, 2014 | IPO on NASDAQ | Transitioned to public ownership; increased investor base. |
| March 31, 2025 | Institutional Ownership Data | Institutional investors hold a significant portion of shares. |
| March 16, 2025 | Founder's Shareholding | Founders maintain notable stakes, indicating long-term alignment. |
As of May 2025, institutional investors hold a substantial portion of Amphastar's shares, with institutional ownership remaining largely unchanged at 73.14%. In March 2025, 555 institutional owners and shareholders held a total of 44,862,704 shares. Key institutional shareholders as of March 31, 2025, include BlackRock, Inc. (6,147,658 shares), Vanguard Group Inc. (2,422,904 shares), TD Asset Management Inc. (2,212,142 shares), and State Street Corp. (1,604,614 shares). Founders still maintain notable stakes in the company. As of March 16, 2025, Dr. Jack Yongfeng Zhang directly owned 5.64% of the company's shares, totaling 2,647,659 shares.
Ownership Structure of Amphastar Pharmaceuticals
Amphastar Pharmaceuticals has a diverse ownership structure, including institutional investors and founders.
- Institutional investors hold a significant portion of the shares.
- Founders maintain notable stakes in the company.
- The IPO in 2014 marked a key shift to public ownership.
- This structure influences the company's strategic direction.
Amphastar Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Amphastar Pharmaceuticals’s Board?
The Board of Directors at Amphastar Pharmaceuticals, a prominent pharmaceutical company, is pivotal in guiding the company's strategic direction. As of April 7, 2025, the board comprises several key figures, including Dr. Jack Yongfeng Zhang, who serves as CEO, President, Chief Scientific Officer, and Director, and Dr. Mary Ziping Luo, the Chief Operating Officer, Chief Scientist, and Chairwoman of the Board. Other members include Richard Prins as Lead Independent Director, along with Dr. Michael A. Zasloff, Dr. Howard Lee, Diane G. Gerst, Floyd F. Petersen, Gayle M. Deflin, Jacob Liawatidewi, and Bill Peters. The board is structured into three staggered classes, with each director serving a three-year term, ensuring continuity and expertise within the company's governance structure. Six of the current directors meet the independence standards set by Nasdaq.
This structure underscores the company's commitment to strong corporate governance and oversight. The board's composition, with a mix of executive and independent directors, facilitates informed decision-making and effective monitoring of the company's performance. Understanding the board's composition is crucial for investors and stakeholders interested in Amphastar ownership and its strategic trajectory. For detailed insights into how Amphastar operates, you can explore Revenue Streams & Business Model of Amphastar Pharmaceuticals.
| Board Member | Title | Role |
|---|---|---|
| Dr. Jack Yongfeng Zhang | CEO, President, Chief Scientific Officer | Director |
| Dr. Mary Ziping Luo | Chief Operating Officer, Chief Scientist | Chairwoman of the Board |
| Richard Prins | Lead Independent Director | Director |
| Dr. Michael A. Zasloff | Director | Independent Director |
| Dr. Howard Lee | Director | Independent Director |
| Diane G. Gerst | Director | Independent Director |
| Floyd F. Petersen | Director | Independent Director |
| Gayle M. Deflin | Director | Independent Director |
| Jacob Liawatidewi | Director | Independent Director |
| Bill Peters | Director | Independent Director |
The voting structure at Amphastar Pharmaceuticals is straightforward, based on a one-share-one-vote principle. Each share of common stock held on the record date entitles the stockholder to one vote. The company does not employ cumulative voting for director elections. To be elected, a director must receive a majority of the votes cast. Abstentions are treated as votes against the director, while broker non-votes have no impact. The board expects directors to resign if they fail to secure the required votes for re-election. Jack Yongfeng Zhang, Mary Ziping Luo, and William J. Peters have been designated as proxies by the Board of Directors, demonstrating the company's commitment to efficient governance and shareholder engagement.
Key Takeaways on Amphastar Pharmaceuticals' Governance
The board's composition and voting structure are designed to ensure accountability and effective oversight.
- The board includes a mix of executive and independent directors.
- Directors are elected through a majority voting system.
- The company follows a one-share-one-vote principle.
- Proxies are designated to facilitate shareholder engagement.
Amphastar Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Amphastar Pharmaceuticals’s Ownership Landscape?
Over the past 3-5 years, the ownership profile of Amphastar Pharmaceuticals has shown dynamic shifts, especially in its share repurchase programs. On June 3, 2024, the Board of Directors authorized a $50 million increase to its share buyback program. This strategic move followed earlier repurchases, with the company buying back $35 million worth of shares by the end of Q4 2024. As of March 2025, the share buyback ratio stood at -0.11%, indicating a slight reduction in outstanding shares due to these repurchases.
A significant acquisition impacted the company's portfolio in April 2023, when Amphastar Pharmaceuticals acquired BAQSIMI from Eli Lilly for over $1 billion. This acquisition has boosted revenue, with BAQSIMI showing a 12% factory sales growth compared to Q4 2023, contributing $41.8 million in direct sales in Q4 2024. These financial maneuvers and strategic acquisitions highlight the active management of the company's capital structure and product portfolio, influencing Amphastar ownership and its market position.
| Metric | Details | Date |
|---|---|---|
| Share Buyback Program Increase | $50 million | June 3, 2024 |
| Shares Repurchased (Q4 2024) | $35 million | Q4 2024 |
| Share Buyback Ratio | -0.11% | March 2025 |
| BAQSIMI Acquisition Value | Over $1 billion | April 2023 |
| BAQSIMI Factory Sales Growth | 12% vs. Q4 2023 | Q4 2024 |
| BAQSIMI Direct Sales | $41.8 million | Q4 2024 |
Leadership changes and insider holdings have also played a role in shaping the company's profile. Dr. Jack Yongfeng Zhang, co-founder, CEO, and Chief Scientific Officer, assumed the role of President on April 10, 2020. Insider holdings have seen minor fluctuations, with a decrease from 9.39% in May 2025. Institutional investors, however, have maintained a steady presence, with their holdings remaining at 73.14% in May 2025. For more insights into the company's financial strategies, explore the Marketing Strategy of Amphastar Pharmaceuticals.
Ownership Structure
Institutional investors hold a significant and stable portion of the company's shares, providing a foundation for stability.
Key Leadership
Dr. Jack Yongfeng Zhang's dual role as CEO and President streamlines the company's management.
Financial Maneuvers
Share buybacks and strategic acquisitions like BAQSIMI demonstrate active capital management.
Future Growth
Ongoing discussions with the FDA regarding its insulin pipeline are expected to drive future growth.
Amphastar Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Amphastar Pharmaceuticals Company?
- What is Competitive Landscape of Amphastar Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Amphastar Pharmaceuticals Company?
- How Does Amphastar Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Amphastar Pharmaceuticals Company?
- What is Brief History of Amphastar Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Amphastar Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.